Morgan Stanley updates ratings, views on European MedTech stocks

Oil prices rose for the third session as US–Iran tensions lifted supply-risk concerns. In European MedTech, Morgan Stanley kept the sector view “In-Line” but made targeted rating/price-target changes: raised Coloplast to Equal Weight with a new target of 454 DKK (from 370), increased ConvaTec to 289 pence (from 263), and lifted Demant to 388 DKK (from 296), while cutting Smith & Nephew to Equal Weight with a reduced target of 1,158 pence (from 1,304). For ConvaTec, the bank highlighted “one-year Infusion Care visibility” and cash-conversion supporting buybacks of ~10% of current market cap over three years, but it flagged Carl Zeiss Meditec as facing another earnings reset with EBITA estimates ~10% below consensus.

Analysis

This is a dispersion setup, not a broad sector call. The cleanest relative winner is the hearing-aid cohort: if unit demand is merely normalizing, the operating leverage sits with the names that can convert incremental volume into earnings fastest, while the market is still paying up for proof rather than paying up for growth. The key distinction is that the upside is front-loaded for companies with near-term savings and mix tailwinds; that favors the lower-latency earnings stories over the longer-dated restructuring narratives.

On the loser side, CZMWY looks like the weakest risk/reward because the next hard catalyst is close, the estimate gap is already meaningful, and the profitability program is too delayed to offset near-term China weakness. That creates a classic setup where sell-side target cuts reduce the floor rather than create one. SNN is different: it is not an imminent blow-up, but the medium-term rebase story means the stock can stay cheap for longer than holders expect, especially if 2026 guidance does not accelerate.

ConvaTec is the most constructive of the single-name longs because capital returns can support the multiple even if top-line growth is modest; however, the buyback story is slow-burn and should not be chased as a near-term rerating catalyst. CLPBY is likely a hold-through-event rather than an outright buy: growth-first messaging can help sentiment, but it also implicitly says margin expansion is not the near-term priority. The market is likely over-focusing on the rating changes themselves and underweighting the importance of actual print dates and strategy days as the real catalysts.

Key Decisions for Investors

• Short CZMWY on any post-upgrade bounce; use the December result as the 1-3 month catalyst window. Risk/reward is attractive because upside needs a China inflection, while downside only requires another cautious print.
• Pair trade: long the hearing-aid basket (Demant/Amplifon/Sonova relative strength) versus short CZMWY. Best expression is 1-3 months, with the thesis breaking if unit demand fails to recover or pricing turns more competitive.
• Start a small long in ConvaTec on pullbacks and add only if buyback authorization or capital-return detail is confirmed. This is a 6-18 month compounding trade, not a tradeable headline pop.
• Avoid chasing CLPBY into the November strategy event; buy only after the event if growth guidance is credible. If the market starts pricing a margin reset instead, the setup turns neutral-to-negative.
• Use SNN as a short-on-strength candidate rather than a momentum long; the rebase is too far out to support a rerating now. Cover only if 2026 guidance steps up materially.